aTYR PHARMA (ATYR) Receivables - Other (2019 - 2026)
aTYR PHARMA's (ATYR) quarterly Receivables - Other came in at $477000.0 in Q1 2026, down 51.72% YoY from $988000.0 in Q1 2025, and up 382.25% on a QoQ basis from -$169000.0 in Q4 2025.
aTYR PHARMA (ATYR) Receivables - Other (2019 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 8 years of Receivables - Other data on file, last reported at $477000.0 in Q1 2026.
- Quarterly Receivables - Other fell 51.72% year-over-year to $477000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $477000.0 (down 51.72% YoY) and the FY2025 annual result came in at $873000.0, down 49.71% from the prior year.
- Receivables - Other grew to $477000.0 in Q1 2026, from -$169000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $11.8 million in Q4 2022 to a low of -$9.9 million in Q1 2023.
- A 5-year average of $948529.4 and a median of $873000.0 in 2022 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other jumped 3748.04% — and 2023, when it tumbled 2419.95%.
- Tracing ATYR's Receivables - Other over 5 years: stood at $11.8 million in 2022, then plunged by 96.11% to $458000.0 in 2023, then tumbled by 120.74% to -$95000.0 in 2024, then slumped by 77.89% to -$169000.0 in 2025, then surged by 382.25% to $477000.0 in 2026.
- The last three Receivables - Other figures came in at $477000.0 (Q1 2026), -$169000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - |
| 10 | aTYR PHARMA | 50.34 Mn | -7.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 426,000.00 |
| Jun 30, 2026 | 426,000.00 |
| Mar 31, 2026 | 477,000.00 |
| Mar 31, 2026 | 477,000.00 |
| Dec 31, 2025 | -169,000.00 |
| Dec 31, 2025 | -169,000.00 |
| Sep 30, 2025 | 1.04 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Mar 31, 2025 | 988,000.00 |
| Mar 31, 2025 | 988,000.00 |
| Dec 31, 2024 | -95,000.00 |
| Dec 31, 2024 | -95,000.00 |
| Sep 30, 2024 | 1.83 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Mar 31, 2024 | 2.48 Mn |